Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Core Insights - Ardelyx, Inc. presented data on IBSRELA (tenapanor) at the ACG Annual Scientific Meeting, highlighting its effectiveness in treating IBS-C and improving patient quality of life [1][2] Group 1: Treatment Satisfaction and Effectiveness - A real-world survey indicated that 88% of patients reported treatment satisfaction with tenapanor, with 95% experiencing improvements in constipation, 75% in bloating, and 84% in abdominal pain [2] - More than 70% of patients noted enhanced ability to engage in daily activities, with 76% stating tenapanor is superior to other IBS-C medications they have used [2] Group 2: Impact on Abdominal Bloating - Data from Phase 3 T3MPO-1 and T3MPO-2 studies demonstrated that tenapanor effectively reduces abdominal bloating, with significant reductions observable as early as the first week of treatment [3] Group 3: Healthcare System Burden - Preliminary findings from an electronic health record study showed a substantial decrease in GI-related clinical encounters and patient portal messaging after the initiation of tenapanor, suggesting a reduction in healthcare resource utilization [4]